State College, PA, United States of America

Mohammad Abu-Laban

This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: The Penn State Research Foundation. Active years: 2023-2025.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Mohammad Abu-Laban

Introduction

Mohammad Abu-Laban is an accomplished inventor based in State College, PA (US). He has made significant contributions to the field of therapeutic and diagnostic delivery systems. With a total of 2 patents, his work focuses on innovative compositions that enhance the effectiveness of medical treatments.

Latest Patents

Abu-Laban's latest patents include compositions and methods for targeted delivery of therapeutic and/or diagnostic species. One aspect of his invention describes a composition that comprises a nanoparticle, a therapeutic species, and a linker that joins the nanoparticle to the therapeutic species. The linker is a product of a Diels-Alder cyclo-addition reaction. In some embodiments, the nanoparticle is a magnetic nanoparticle, which adds a unique dimension to the targeted delivery system.

Career Highlights

Mohammad Abu-Laban is associated with the Penn State Research Foundation, where he continues to advance his research and innovations. His work is pivotal in developing new methods for delivering therapeutic agents effectively.

Collaborations

Abu-Laban collaborates with various professionals in his field, including his coworker Daniel Hayes. Their combined expertise contributes to the success of their research initiatives.

Conclusion

Mohammad Abu-Laban's innovative work in targeted delivery systems showcases his commitment to advancing medical technology. His contributions are significant in the realm of therapeutic and diagnostic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…